PKMYT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Meisoindigo targets PKMYT1 for degradation by acting as a molecular glue that enhances PKMYT1‐TRIM25 interaction, leading to K48‐linked ubiquitination and subsequent proteasomal degradation, thereby exerting therapeutic effects in chronic myeloid leukemia.